IRS agrees to waive some device tax penalties; HeartWare's shares rise and fall on rumors;

 @FierceMedDev: NanoString Cancer Dx passes second large-scale test. Article | Follow @FierceMedDev

@MarkHFierce: A $3M Series B round goes to Wright Therapy, which makes lymphedema compression products. Safe, steady investment. Release | Follow @MarkHFierce

 @DamianFierce: Get used to this headline: Startup raises money for renal denervation device. More | Follow @DamianFierce

> For the first three quarters of 2013, the IRS plans to waive penalties for the new medical device industry tax in most cases as companies work to comply with the new requirement. Story

> Medtronic ($MDT) debuted a new surgical technique to stabilize the cervical spine. Release

> Australia and New Zealand are making progress in their development of a joint regulatory agency for "therapeutic products" including medical devices. Item

> HeartWare's ($HTWR) stock has been on a roller-coaster ride since the FDA approved its HVAD device Nov. 20, in part because of fears over stroke risks. Story (subs. req.)

> Endocyte ($ECYT) VP Christopher Leamon writes in Wired about the growing importance of companion diagnostics and personalized medicine. Column

> AFrame snagged FDA clearance for its wristwatch-based MobileCare Monitor. News

> The chorus is getting louder to focus more of device innovation on "value." Story

Biotech News

 @FierceBiotech: Breast cancer vaccine developer bags Teva Pharma, Dx deals to bolster PhIII program. Story | Follow @FierceBiotech

@JohnCFierce: Scientists want more work on apoE as Alzheimer's target (amyloid/tau top suspects) Helps illustrate all the confusion. More | Follow @JohnCFierce

 @RyanMFierce: This Pfizer robbery gives new meaning to a favorite phrase of mine: Pharma gold. Report | Follow @RyanMFierce

> BioCryst Pharma chops half of staff to cap tumultuous two months. Article

> Ecstasy ingredient green-lighted for controversial PTSD study. Report

> Billionaires bankroll R&D institute for Merck KGaA's doomed Geneva facility. News

Pharma News

@FiercePharma: GSK loses class-action ruling on Paxil in Canada. News | Follow @FiercePharma

> Mylan tries snatching Ranbaxy's rights to Novartis blockbuster. Article

> Amarin's fish oil future gets slippery with $100 million in debt. Story

> NICE snubs Pfizer's Inlyta kidney cancer drug. Report